Varner R Edward, Ireland Christine C, Summitt Robert L, Richter Holly E, Learman Lee A, Vittinghoff Eric, Kuppermann Miriam, Washington Eugene, Hulley Stephen B
Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 619 South 19th Street, NHB-219, Birmingham, AL 35249-7333, USA.
Control Clin Trials. 2004 Feb;25(1):104-18. doi: 10.1016/j.cct.2003.08.008.
Hysterectomy may be overused as treatment for abnormal uterine bleeding due to benign causes in reproductive women. Medical therapies are an alternative, and there is a need for randomized trials comparing the outcomes of these approaches. Women of reproductive age who continued to have bothersome abnormal uterine bleeding after cyclic hormonal treatment with medroxyprogesterone acetate (MPA; 10-20 mg for 10-14 days/month) for 3-5 months were invited to participate in a randomized trial of hysterectomy versus other medical therapies. Participating gynecologists were free to choose the particular surgical (transabdominal or transvaginal) or medical (generally oral contraceptives and/or a prostaglandin synthetase inhibitor) approaches. Outcomes during 2 years of follow-up include quality of life (primary), sexual function, clinical effectiveness and cost. We screened 1557 women to find 413 who began 3-5 months of MPA; 215 completed this treatment, of whom 102 still had bothersome symptoms, and of these 38 consented to be randomized. Another 25 women with bothersome symptoms after a documented history of 3 months of cyclic MPA were also randomized, for a total of 63. The average age of randomized women was 41; 54% were African-American, and they reported uterine bleeding 12 days/month on average, heavy bleeding 6 days/month. Anemia (hematocrit<32) was present in 38% of African-Americans and 15% of Caucasians (p=0.05). Two thirds of the women had fibroids and 80% reported pelvic pain. Obesity was common (45% had a body mass index (BMI)>30), and associated with a longer duration of symptoms (12 vs. 4 years for BMI<25; p=0.02) and a greater prevalence of incontinence (44% vs. 16%; p=0.046). Although recruitment was difficult, we have completed enrollment in a randomized clinical trial comparing surgical and medical treatments for abnormal uterine bleeding.
子宫切除术可能被过度用于治疗生育期女性因良性原因导致的异常子宫出血。药物治疗是一种替代方法,因此需要进行随机试验来比较这些治疗方法的效果。在接受醋酸甲羟孕酮(MPA;10 - 20毫克,每月10 - 14天)进行3 - 5个月的周期性激素治疗后仍有令人烦恼的异常子宫出血的育龄女性被邀请参加一项子宫切除术与其他药物治疗的随机试验。参与试验的妇科医生可自由选择特定的手术方式(经腹或经阴道)或药物治疗方式(通常为口服避孕药和/或前列腺素合成酶抑制剂)。2年随访期间的结果包括生活质量(主要指标)、性功能、临床疗效和成本。我们筛查了1557名女性,找到413名开始接受3 - 5个月MPA治疗的女性;215名完成了该治疗,其中102名仍有令人烦恼的症状,这102名中有38名同意参加随机分组。另有25名在有记录的3个月周期性MPA治疗史后有令人烦恼症状的女性也被随机分组,共计63名。随机分组女性的平均年龄为41岁;54%为非裔美国人,她们平均每月有12天子宫出血,其中6天为大量出血。38%的非裔美国人和15%的白种人存在贫血(血细胞比容<32)(p = 0.05)。三分之二的女性有子宫肌瘤,80%报告有盆腔疼痛。肥胖很常见(45%的人体重指数(BMI)>30),且与症状持续时间较长(BMI<25者为4年,BMI>30者为12年;p = 0.02)以及尿失禁患病率较高(44%对16%;p = 0.046)相关。尽管招募困难,但我们已完成一项比较异常子宫出血手术治疗和药物治疗的随机临床试验的入组工作。